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1. Introduction 
Methicillin resistant Staphylococcus aureus 
(MRSA) have recently emerged in food 
producing animals. The emergence of this 
potential zoonotic pathogen in animals has 
raised the concerns of potential transmission to 
humans from the animal reservoirs and 
consequences on Public Health. In 2008, the 
European Commission (EC) took a decision of 
screening the population of pig farms in Europe 
for this new emerging pathogen, taking this 
screening into the framework of the baseline 
screening for Salmonella in pig farms 
(European Commission Decision 2008/55/EC). 
This screening has been performed in most 
European Countries by laboratories appointed 
by the national authorities and according to a 
common protocol defined by the EC. 
The European Union Reference Laboratory for 
Antimicrobial Resistance (EURL-AR) took part 
in the development and support of the 
laboratories for this task by providing 
assistance in setting up the methods for 
isolation, identification, and typing of MRSA. 
Additionally, the EURL-AR provided training in 
the specific methods on individual basis as well 
as in an MRSA training course that was 
organized in April 2009. 
In June 2009, the EURL-AR in addition to the 
External Quality Assurance System (EQAS) 
already performed, launched an MRSA specific 
EQAS, to enhance the capacity of the 
laboratories in MRSA isolation, identification 
and typing. This EQAS aimed at the 
identification of potential problems and 
identification of focus areas for 
training/education that might improve data 
quality in future European studies focusing on 
MRSA epidemiology. 
In June 2010, a trial was prepared in October 
2010, using swab samples. Since then, swab 
samples were used within the EQAS trial. 
In 2012, we launched the fourth EQAS 
performed on MRSA isolation, identification and 
typing. As the previous EQAS, this included 
isolation steps besides the identification and 
also a molecular component; detection of 
methicillin resistance. The detection of the 
mecA and mecC gene were included as a 
mandatory part for confirmation of MRSA. An 
optional sequence based typing module based 
on spa typing was also offered. The spa typing 
trial aimed at increasing the capacity of 
laboratories by performing a standard typing 
method which can be easily performed, and 
which results are comparable and useful to 
assess the epidemiology of MRSA in Europe.  
At the starting point of this EQAS, the 
laboratories should have implemented the 
methods and enhanced its performance. 
Therefore, the EQAS may be used to assess 
the quality of data provided to EFSA, but also to 
prepare the laboratories for correctly performing 
the isolation, identification and molecular 
detection of MRSA. 
No thresholds have been set in advance to 
evaluate the performance of the participating 
laboratories, nor classify the results of this 
EQAS as there were issues related to stability 
which have caused deviations.  
The MRSA EQAS was organized by the 
National Food Institute (DTU Food), Kgs. 
Lyngby, Denmark and the 
verification/confirmation of the strains used in 
the preparation of the test samples was 
performed at the Statens Serum Institute (SSI) 
in Copenhagen, Denmark. 
The data in this report are presented with 
laboratory codes. A laboratory code is known to 
the individual laboratory, whereas the entire list 
of laboratories and their codes is confidential 
and known only to the EURL-AR and the EU 
Commission. All conclusions are public.  
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The technical advisory group for the EURL-AR 
EQAS scheme consists of competent 
representatives from all National Reference 
Laboratories for Antimicrobial Resistance 
(NRLs-AR), who meet annually at the EURL-AR 
workshop
2. Materials and Methods  
2.1 Participants in EQAS 2012 
A pre-notification (App 1), inviting the 
participants to the MRSA EQAS 2011 was 
issued by e-mail to the EURL-AR network on 
the 16th of July 2012 to the NRL-AR’s. 
Additionally, the laboratories that participated in 
the MRSA baseline studies in 2008 and 
participated in the MRSA EQAS in the previous 
year were invited to participate using the same 
pre-notification. 
All participants were included in a participant list 
(App 2) before the preparation and shipping of 
the samples. Participation was free of charge 
but each laboratory was expected to cover 
expenses associated with their own analysis.  
2.2 Preparation of samples 
Eight swab samples were prepared and 
dispatched for isolation of MRSA, identification, 
and typing of the obtained isolates. The 
samples were artificially prepared to contain 
either methicillin-resistant Staphylococcus 
aureus (MRSA), methicillin-susceptible S. 
aureus (MSSA) and/or coagulase negative 
staphylococci strains (CNS), and, for the first 
time, we have also included samples containing 
a methicillin resistant Staphylococcus carrying 
the mecC gene and a methicillin resistant 
Staphylococcus pseudointermedius strain. 
Selected strains were then used as test strains 
and mixed in a sample containing a background 
flora composed of a mix of S. sciuri, 
Enterococcus faecalis and Escherichia coli 
which was intended to mimic the normal flora 
that would be present in a nasal swab collected 
from an animal.  
The background flora was prepared by 
matching bacterial suspensions of E. faecium 
NS13 (isolate originated from a nasal swab 
from a pig); Staphylococcus sciuri NS 72 
(isolate originated from a nasal swab from a 
pig) and Escherichia coli ATCC 25922  to a 0,5 
Mc Farland standards suspension which were 
then diluted to 10-3 in saline and mixed in equal 
parts. The swabs were dipped into this mixture 
before preparation of the samples. The 
expected amount of each bacterial culture in 
the mixture was about 105 CFU/ml. This was 
confirmed by performing serial dilution and 
colony forming unit counts in duplicate from all 
bacterial suspensions. 
The test isolates selected for the MRSA EQAS 
(EURL-MRSA 4.1- EURL-MRSA 4.8) were 
prepared in advance and subcultured in week 
38-39 and re-subcultured on the day before 
sample preparation. For the sample 
standardization, suspensions equal to 
McFarland 0.5 were prepared in saline tubes of 
the relevant isolates to contain about 108 
CFU/mL. The suspensions were further diluted 
1:10 or 1:100 (in the case of the inoculum for 
samples 4.8) to 107 CFU/ml or 10 CFU/mL of 
which 100 µl were used to inoculate the 
transport media contained in the tubes with the 
swab samples. The expected inoculum was 
expected to be about 106 CFU per sample, for 
samples 4.1, 4.2, 4.3, 4.4, 4.5 and 4.6, and it 
was about 105 CFU per sample, for sample 4.8 
confirmed by performing serial dilution and 
colony forming unit counts in duplicate from all 
isolate suspensions. The sample MRSA EQAS 
4.7 contained only the background flora and no 
added test organism. 
The strains used for the EQAS were selected 
from the strain collections at DTU-Food and the 
identification were confirmed by PCR and 16S 
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rDNA. Furthermore, the spa type of the MRSA 
isolates was determined by PCR and 
sequencing and assigned according to the spa 
server using Bionumerics (App 3). Identification 
and the spa type of the selected isolates were 
verified and confirmed by parallel analysis  
conducted at SSI, Copenhagen, Denmark. The 
results obtained after preparation of the 
contaminated swab samples were confirmed at 
DTU-Food, by testing (isolation, identification 
and typing) of three sample sets just after 
preparation. Stability testing was performed in 
one set of eight samples per week, during one 
month. Further tests were performed after six 
and eight weeks using the recommended 
protocol for isolation and identification of 
MRSA. Further stability tests revealed good 
stability up to week six for all the samples and 
up to week eight for most samples, except for 
samples 4.3, 4.6 and 4.8 for which we detected 
lack of stability eight weeks after shipping. 
2.3 Isolation and identification of 
MRSA from swab samples 
The protocol for isolation and identification of 
the MRSA isolates contained in the swab 
samples was made available on the EURL 
website  (http://www.eurl-ar.eu) (App.4). This 
time, the protocol for identification of methicillin 
resistance has been modified by recommending 
a new multiplex PCR able to detect both mecA 
and mecC genes and to simultaneously amplify 
fragments of the spa and pvl genes (Stegger et 
al., 2012).  
2.4 Typing 
The isolates used for the sample preparation 
were typed by a single locus sequence typing 
method - spa typing (Shopsin et al. 1999) and 
in addition to verification of spa types at the 
SSI, the spa typing results were verified a third 
time in the isolates obtained from prepared 
samples. 
The laboratories with capacity to perform spa 
typing were invited to also include the spa 
typing results to the MRSA EQAS database, 
which were evaluated for accuracy against the 
expected spa types. 
2.5 Distribution 
The samples were prepared a week before 
shipment and were kept at 4°C between the 
preparation and shipment process. The tubes 
containing the swab samples in transport media 
were enclosed in double pack containers (class 
UN 6,2) and sent to the selected laboratories 
according to the International Air Transport 
Association (IATA) regulations as “Biological 
Substance category B” classified UN3373. The 
parcels were dispatched from DTU-Food 
October 1st, 2012. 2.6 Procedure 
The laboratories were instructed to download 
the protocol and test forms (App. 4 and 5), from 
http://www.eurl-ar.eu 
The EQAS protocol was based on the EC 
baseline protocol for isolation of MRSA from 
dust samples, however, with slight changes in 
the volume of the media needed in the 
enrichment steps, since the samples were sent 
as swab samples in a tube containing transport 
medium in contrast to large dust swabs. The 
method recommended for the identification of 
the isolates was a new multiplex PCR which 
would allow identification of S. aureus and also 
identify the mecA and mecC genes, mandatory 
for the classification of isolates as MRSA (App 
4). 
After completion of the tests, the laboratories 
were requested to enter the obtained results 
into an electronic record sheet in the EURL-AR 
web based database through a secured 
individual login, or alternatively send the record 
sheets by fax to DTU Food (App 5). The 
database was activated 17th October, 2012 and 
closed December 22nd 2012. 
The samples were categorised as positive or 
negative in function of the isolation and 
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identification of MRSA isolates and no 
quantitative variable was introduced. Negative 
samples could be subdivided into different 
categories (negative sample, MSSA, MRCNS, 
MRSP, CNS), however they would be grouped 
as negative. Final interpretations of the results 
obtained were compared to the expected 
results and classified as correct or incorrect, 
without further classification of the deviation.  
Optionally, results of spa types were requested 
for typing the positive MRSA samples. In this 
case, the participants would be invited to 
choose the obtained spa type from a pick list, 
and the typing result would be evaluated 
against the expected spa type and classified 
into correct or incorrect.  
3. Results 
A total of 33 laboratories; including 21 NRLs, 
seven additional non-NRLs in EU and 
laboratories from Croatia, Norway, Serbia, 
Switzerland and Turkey responded to the pre-
notification, and were enrolled in the EQAS.  
When the deadline for submitting results was 
reached, 27 laboratories in 25 European 
countries (including Croatia, Switzerland and 
Norway) had uploaded data. One of the 
laboratories decided not to take part (Lab #52) 
and four laboratories (Labs #37, #40 and #54, 
#57) did not upload results data due to 
technical issues.  
One laboratory or more from the following 
countries provided results to at least one of the 
EQAS components (also shown below in Figure 
1): Austria, Belgium, Croatia, Czech Republic, 
Denmark, Estonia, Finland, France, Germany, 
Hungary, Ireland, Italy, Latvia, Lithuania, the 
Netherlands, Norway, Poland, Portugal, 
Romania, Slovakia, Slovenia, Spain, Sweden, 
Switzerland, and UK. 
 
Figure 1. Participating countries in MRSA EQAS 2012. Participating countries are marked in green for laboratories 
participating in MRSA isolation and identification.Dark blue represents countries participating in the spa typing. 
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3.1 Methods used by EQAS-
participants 
Of the 27 laboratories submitting results all 
(100%) of the laboratories participated in the 
MRSA isolation and identification module 
whereas only 18 laboratories (67%) participated 
in the optional spa typing module offered. 
Information on the methods used for isolation, 
identification and typing was collected from the 
participants through the database.  
Most laboratories (n=21) reported that isolation 
has been performed according to the protocol 
provided by the EURL-AR for this EQAS and 
any changes in media, concentrations of 
antibiotics, etc. were referred. The differences 
reported by some laboratories from the method 
described in the original protocol were: use of 
6.0% salt (Lab#17), use of 5.0 µg/ml cefoxitin 
(Lab #55, use lower concentration of aztreonam 
at 50mg/L (Lab #17) of phenol red mannitol 
broth with 5.0 µg/ml ceftizoxime and 75 µg/ml 
aztreonam. In one lab (Lab #17) the selective 
medium was modified by using a lower 
concentration of aztreonam of 50 µg/ml and 6.0 
% NaCl (instead of 6.5 %) was added to the 
MH-pre-enrichment broth which was incubated 
24h and then further 24h if growth was 
negative. Different selective plates for the 
selective isolation, included CHROMagar 
MRSA (Mast Diagnostica), BD MRSA Chrom 
Agar (BD); Chrom ID MRSA Agar (bioMérieux), 
ORSA (Oxoid) , MRSA Select (Bio RAD) and 
Baird Parker agar plates.  Some laboratories 
indicated they use different volumes of media in 
the enrichment steps, and others do perform 
additional cultures on blood agar to observe 
typical growth of Staphylococcus aureus. 
The confirmatory testing of S. aureus was 
performed using the new EURL-AR 
recommended PCR containing the mecA, 
mecC, pvl and spa gene in most laboratories 
uploading results (n=16) and the other referred 
methods for identification included the old 
EURL-recommended method (n=5), other 
published (n=1) or in-house PCR and RT-PCR 
methods (n=4) and one did not reply. 
The species identification was mostly 
performed by PCR, using the EURL 
recommended PCR primers (n=13), however 
seven laboratories have still used the old 
protocol for this purpose. Other methods 
included using other published or In-house PCR 
methods in the remaining laboratories that 
reported methods (n=3) and biochemical 
reactions (n=2). 
Table 1. The overall performance of MRSA isolation and identification, 2012. 
Isolation of MRSA from swab samples Correctly classified samples 
Number of performed tests Number of correct tests N(%) 
n % N % 
215 100 200 93 
Number of expected negative tests Number of correctly identified negative tests 
n % N % 
81 38 78 96 
Number of expected positive tests Number of correctly identified positive tests 
N % N % 
134 62 122 91 
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3.2 MRSA isolation and 
identification 
A total of 215 tests (most laboratories have 
reported results for all the eight samples and 
only Lab #23 uploaded results for all samples 
except for sample nr 4.3) have been performed 
and the overall result indicate that 200 tests 
were correct, corresponding to 93%. From the 
81 samples expected to be negative 96% 
(n=78) were correctly assigned, and the 
remaining three were found false positive. 
Regarding the samples expected to be found 
positive, there were 91% of these found positive 
(n=122) (Table 1). 
As described above, most deviations were 
caused by a lack of sensitivity of the methods 
used, leading to false negative results in 12 
samples in total whereas the results deviating 
due to false positives were only three. Among 
the laboratories with two deviations, one 
participant (Lab # 21) reported that the 
deviations were due to mistakes occurred in the 
transcription of the results and reporting phase 
for one sample and /or cross contamination of 
one of the samples. 
The results per sample show that most 
deviations were observed for samples EURL-
MRSA 4.3 (n=6) and EURL-MRSA 4.8 (n=5) 
which both contained an MRSA (Graph 1). Four 
laboratories of the laboratories obtaining 
deviation for sample 4.3 have obtained 
deviations by considering it an MSSA. One 
probable explanation for this is that the EURL-
MRSA 4.3 contained an MRSA which carried 
the new mecC gene, and some of the 
laboratories might not have optimized the 
methods for its confirmation as methicillin 
resistant. The two remaining laboratories have 
not found any isolate in this sample, which 
might be related to lack of sensitivity in the 
method used. Three participants did not find 
any Staphylococci strains in sample 4.8 (Labs 
#2, 22 and 35) and further two have either 
reported MSSA or CNS as a result for this 
sample (Labs #20 and 56), respectively. This 
might have been partially caused by this 
sample having been inoculated with a lower 
inoculum, at circa 105 cfu per sample. In the 
stability testing of these samples, Both samples 
4.3 and 4.8 showed good stability until the sixth 
week after preparation (5th November 2012) but 
both could not be retrieved on the eight week 
(19th November 2012). As part of the EQAS 
instructions, the laboratories had received 
indications to process the samples as soon as 
possible after reception, thus we expect the 
samples would have been processed early after 
reception and therefore do not consider this late 
stability loss as cause of deviations. However, 
the data collected from the laboratories did not 
contain the date of isolation and therefore we 
cannot be totally sure if the stability could have 
interfered in some results.  Moreover, there was 
only one more false negative result for sample 
4.1 and all samples had been prepared in the 
same way and on the same day, following 
equivalent procedures (except for the lower 
inocullum in sample 4.8). Regarding sample 4.5 
and 4.7, two and one deviations were observed, 
respectively, meaning that MRSA was found in 
these samples which were expected to be 
negative for MRSA. These results must have 
been caused by either cross contamination or 
switch between samples or data. (Graph 1). 
As for the sample 4.6 containing the methicillin 
resistant Staphylococcus pseudointermedius 
(MRSP) strain, no deviations were reported, 
meaning that this strain was not reported 
wrongly as a MRSA. However, the negative 
results reported vary between the most correct 
classification as MRSP (n=14), mecA positive 
but coagulase negative (n=7), mecA and mecC 
negative and not S.aureus (CNS) (n=1), and no 
isolate found (n=1). 
An internal control was prepared in order to 
have one strain in common to both MRSA 
EQAS 2009 and 2010 trials. The internal control 
was shipped within sample EURL-MRSA 4.1, 
which contained the same MRSA spa t075 
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strain sent in 2009 as CRL-MRSA 1.3 and in 
2010 as EURL-MRSA 2B.7. Only one deviation 
was found for this sample. Furthermore, unlike 
last year, there were no issues regarding 
stability of samples containing this strain. 
In general, the individual laboratory results of 
this MRSA EQAS on isolation and identification 
of MRSA from swab samples, showed a very 
good specificity by most laboratories. This was 
observed in most laboratories provided that 
only three false positives were observed.  
However, the sensitivity was slightly lower and 
12 of the samples expected to be positive were 
misclassified. The remaining laboratories had 
between one and two deviations only, among 
the eight samples shipped (Graph 2 and 3). 
One laboratory, Lab #23 has only submitted the 
final interpretation for seven of the positive 
samples (all except 4.3) and has therefore only 
reported seven correct results, although no 
deviating results were reported.  
3.3 spa typing of the MRSA strains 
The spa typing module accounted participation 
of 18 laboratories, which have uploaded spa 
typing data.  
The reported results for spa typing included 106 
tests and the general results show that 99 
(93%) of results were considered correct 
whereas 7 (7%) deviation were observed. This 
time four of the participants were able to 
correctly assign all the eight samples, which is 
a clear improvement. Other nine laboratories 
did not have any deviations either, however, 
these laboratories uploaded results for two to 
six samples.  
In this module, samples EURL-MRSA-4.1, 
EURL-MRSA-4.2, EURL-MRSA-4.3 and EURL-
MRSA-4.4 and EURL-MRSA 4.8 were identified 
positive for MRSA. Therefore, optional spa 
typing was offered for the respective isolates 
found, whereas the remaining negative samples 
EURL-MRSA-4.5, EURL-MRSA-4.6 and EURL-
MRSA-4.7 would not render a positive MRSA 
isolate for typing and therefore be classified as 
N/A (not applicable) (Table 2).  
Some of the laboratories have only reported the 
results regarding the sample previously found 
positive for MRSA, whereas no more than eight 
have reported Not applicable results for all the 
samples considered MRSA negative, as 
required. In this way the range of uploaded spa 
types diverged from one to eight samples, 
uploaded by each participating lab.  
By laboratory, the results show that 13 
laboratories did not have any deviations. Seven 
participants uploading spa typing data have 
obtained some deviations (ranging from 0-2 
deviations per lab), mostly related to the lack of 
isolation of the expected MRSA (false 
negatives, which were therefore not spa typed) 
Graph 4 and 5). Lab #22 has only uploaded 
results for spa typing of EURL-MRSA 4.7 and 
EURL-MRSA 4.8 which was incorrectly 
assigned, and has therefore obtained 50% 
deviation, however representing one deviation 
only. Laboratories with deviations in the spa 
typing module were as follows Labs #12, 21, 
22, 35 and 50. As for the causes of deviation,  
 
 
 
Graph 2: Number of deviations per laboratory for 
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Graph 3: Deviating results per laboratory. The laboratories were ranked by decreasing percentage of deviation. 
 
Table 2. Results of the spa typing trial per sample. 
Sample 
number 
N 
participating 
laboratories 
Repeat succession expected spa type correct 
Deviating 
results 
(number of 
deviations) 
EURL-MRSA 4.1 15 11-19-21-21-12-21-17-34-24-34-22-25 t075 13 N/A (2) 
EURL-MRSA 4.2 15 08-16-02-25-02-25-34-24-25 t034 15 None 
EURL-MRSA 4.3 14 04-82-17-25-17-25-25-16-17 t843 12 N/A (1) t034 (1) 
EURL-MRSA 4.4 15 08-16-02-25-02-25-34-24-24-25 t1793 15 None 
EURL-MRSA 4.5 9 None (MSSA) N/A 8 t127 (1) 
EURL-MRSA 4.6 11 None (MRSP) N/A 11 None 
EURL-MRSA 4.7 11 None (blank) N/A 11 None 
EURL-MRSA 4.8 15 08-16-02-25-02-25-34-24-25 t034 13 N/A (2) 
N/A- not applicable 
Graph 4- Deviating results for spa typing, per participating laboratory. The laboratories were ranked by decreasing 
percentage of deviation. Note: Lab #22 has only uploaded results for two spa typed samples of which one was found 
wrong, therefore, showing a 50% deviation, even though it represents only one deviation.   
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Graph 5: Number of deviations per laboratory for spa 
typing. 
four of the deviations were caused by lack of 
isolation of the expected MRSA isolates and 
uploading a spa typing result as Not applicable. 
One additional deviation was caused by 
considering spa type as Non applicable. The 
Opposite also happened, by one participant 
reporting a spa type for a S. aureus isolated as 
a false positive. At last one deviation was 
actually caused by wrong spa type assignment. 
Meaning that the spa type reported was 
different from the expected one. 
4. Discussion
4.1 MRSA isolation and 
identification 
In the 2012 EURL-AR MRSA EQAS trial, the 
samples were prepared with strains selected 
based on recent findings and the quantity 
inoculated was increased 10 times (inoculum of 
circa 106 cfu/sample) for the samples EURL-
MRSA 4.1, 4.2, 4.3, 4.4, 4.5 and 4.6 and 
maintained at the main level used in 
2011(approximately 105 cfu/sample) for sample 
EURL-MRSA 4.8. This has reduced the 
problems experienced in the past with lack of 
sensitivity.  
The results were overall very good and both 
expected negative and expected positive 
samples were mostly well classified, with few 
exceptions of 12 false negative and two false 
positive results. However, the level of 
contamination of the samples used in this 
EQAS iteration was rather high, therefore we 
believe there would be still be a need to further 
improove the sensitivity of the method as we 
have seen previously that sensitivity declined 
when samples with lower innoculum were 
analyzed (as observed in MRSA EQAS 2011). 
4.2 spa typing 
For spa typing, 18 laboratories participated in 
the trial which indicates a slightly increase in 
participation. The results uploaded were 
excellent, with thirteen of the 18 laboratories 
showing no deviation. The range of uploaded 
results by the participating laboratories was 
very broad and most deviating results were 
caused by lack of isolation of the MRSA, one 
was caused by lack of spa typing, another by 
typing an S. aureus from a false positive 
isolation and only one deviation was actually 
were caused by wrong spa type assignment.  
Most deviations observed do not demonstrate 
any problems with the spa typing method, but 
reflect only a small issue concerning possible 
cross contamination or sample management 
that might have caused the deviation observed 
in one of the spa types found incorrect (found 
spa type could be from MRSA in another 
sample from this EQAS). 
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5. Conclusion 
In general, the results of the fourth MRSA 
EQAS 2012 demonstrate that most participating 
labs have set up the methods and are able to 
isolate MRSA from swab samples in a reliable 
fashion. Furthermore, the identification of 
MRSA using molecular methods is performed 
successfully in most the participating 
laboratories, with excellent specificity, and 
improved test sensitivities. However the 
methodology itself still might call for further 
optimization. 
The participation in the spa typing module has 
increased indicating that more laboratories 
have this method available among the 
laboratories in Europe. However, still nine 
laboratories participating in the MRSA EQAS 
2012 did not take part in this optional module. 
This might indicate that these laboratories have 
difficulties in performing spa typing and/or have 
not set up this methodology.  
The results of this module show that spa typing 
as expected is a reproducible method which did 
not cause major problems relative to the 
execution or interpretation in the participating 
laboratories. Most deviations observed in this 
module were due to lack of isolation of the 
MRSA and therefore as a result of false 
negative results. One additional deviation was 
due to false positive result in isolation. The only 
deviation observed which were due to wrong 
spa type assignment might be due to possible 
switching of samples or cross contamination 
between samples within the EQAS samples, 
which again shows the need of controlling the 
analysis process in every step, to obtain a 
reliable final result. 
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Appendix 1-EURL-AR MRSA EQAS 2012 pre-notification  
EXTERNAL QUALITY ASSURANCE SYSTEM (EQAS) 2012 FOR DETECTION OF 
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN SWAB SAMPLES 
The EURL-AR is pleased to announce the launch of the fourth MRSA-EQAS trial. The EQAS 
provides the opportunity for proficiency testing, which is considered an important tool for the 
production of reliable laboratory results of consistently good quality. This EQAS offers detection, 
identification and typing of MRSA from eight samples which contain a background flora and of 
which some will contain MRSA. The samples will be swabs in tubes containing transport medium  
This EQAS is specifically for designated NRL-ARs and additional designated laboratories 
performing the selective isolation and identification of MRSA from pig farms. These laboratories 
do not need to sign up to participate but are automatically regarded as participants. You may contact 
the EQAS-coordinator, if you wish to inform of changes. If you have not participated in the MRSA 
EQAS 2011, you are welcome to contact us to sign up for the participation in this EQAS. 
Participation is free of charge for all above-mentioned designated laboratories.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
Please remember to provide the EQAS coordinator with documents or other information that can 
simplify customs procedures (e.g. specific text that should be written on the invoice). As means of 
avoiding passing the deadline we ask you to send us this information already at this stage. For your 
information, the content of the parcel is UN3373 “Biological Substance Category B”. 
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The samples will be shipped in October 2012. The protocol will 
be provided via our website. This year protocol, as in the previous trials will be based on the 
protocol used in the baseline studies for the isolation procedure and therefore we would like to ask 
you to have the same media referred in the baseline protocol and any materials or reagents needed 
for the selective isolation procedure should be readily available for processing the samples which 
will need to be processed right upon arrival.. The confirmatory PCR method recommended will be 
modified this year, due to the inclusion of MRSA carrying the novel gene mecALGA251 (mecC). 
Therefore a new protocol for the PCR will be posted on our website and the mecC controls 
distributed within the shipments of the test samples for this EQAS.  
Returning of results: Results must be returned to the National Food Institute by December 14th 
2012. Upon reaching the deadline, each participating laboratory is kindly asked to enter the 
password-protected website once again to download an automatically generated evaluation report. 
EQAS report
Any comments regarding the EQAS, please contact me by e-mail (licav@food.dtu.dk) or by 
fax (+45 35 88 63 41). 
: When the EQAS is concluded, the data will be collected in an overall report in which 
it is possible to see all participants’ results in comparison. In the report the laboratories will be 
coded, thus ensuring full anonymity; only the National Food Institute and the EU Commission will 
be given access to un-coded results. 
Sincerely, 
Lina Cavaco 
MRSA EQAS-Coordinator 
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Appendix 2- Participant list 
registered 
Isolation 
MRSA 
spa typing Institute Country 
X X X Austrian Agency for Health and Food Safety Austria 
X X X Veterinary and Agrochemical Research Centre Belgium 
X 
  
National Diagnostic and Research Veterinary Institute Bulgaria 
X X 
 
Croatian Veterinary Institute Croatia 
X X 
 
SVI Olomouc Czech Republic 
X X X The National Food Institute Denmark 
X X X Estonian Veterinary and Food Laboratory Estonia 
X X X Finnish Food Safety Authority EVIRA Finland 
X X X ANSES (French Agency for Food, Environmental and occupational Health & Safety). France 
X X X Federal Institute for Risk Assessment Germany 
X X X Central Agricultural Office, Veterinary Diagnostical Directorate Hungary 
X X 
 
Central Veterinary Research Laboratory Ireland 
X X X Istituto Zooprofillatico Sperimentale Delli Regioni Lazio e Toscana Italy 
X X X National Diagnostic Centre of Food and Veterinary Service Latvia 
X X 
 
National Food and Veterinary Risk Assessment Institute Lithuania 
X X 
 
Central Veterinary Institute of Wageningen Netherlands 
X X X Faculty of Veterinary Medicine Utrecht Netherlands 
X X 
 
Food and Consumer Product Authority (VWA) Netherlands 
X X X Veterinærinstituttet Norway 
X X 
 
National Veterinary Research Institute Poland 
X X X Faculdade de Medicina Veterinária- UTL Portugal 
X 
  
Laboratório Nacional de Investigacão Veterinária (LNIV) Portugal 
X X 
 
Institute for Diagnosis and Animal Health Romania 
X 
  
Institute of Veterinary Medicine of Serbia Serbia 
X X 
 
State Veterinary and Food Institute (SVFI) Slovakia 
X X 
 
National Veterinary Institute Slovenia 
X X X Complutense University of Madrid Spain 
X X X National Veterinary Institute, SVA Sweden 
X X X Vetsuisse faculty Bern, Institute of Veterinary Bacteriology Switzerland 
X   National Food Reference Laboratory Turkey 
X X X The Veterinary Laboratory Agency United Kingdom 
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Appendix 3 –Expected results MRSA EQAS 2012 
  
Sample mecA mecC spa type MRSA status sample 
MRSA EQAS- 4.1 positive negative t075 Positive 
MRSA EQAS- 4.2 positive negative t034 Positive 
MRSA EQAS- 4.3 negative positive t843 Positive 
MRSA EQAS- 4.4 positive negative t1793 Positive 
MRSA EQAS- 4.5 negative negative N/A (t127) 
Negative 
(MSSA) 
MRSA EQAS- 4.6 positive negative N/A Negative 
(MRSP) 
MRSA EQAS- 4.7 N/A N/A N/A Negative (blank) 
MRSA EQAS- 4.8 positive negative t034 Positive 
N/A- not applicable 
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Appendix 4- Protocol for MRSA EQAS 2012 
 
For selective isolation, detection and typing of methicillin resistant Staphylococcus aureus (MRSA) 
from swab samples. 
 
 
1 INTRODUCTION .................................................................................................................................................... 1 
2 OBJECTIVES ........................................................................................................................................................... 2 
3 OUTLINE OF THE MRSA EQAS 2012 ................................................................................................................. 2 
3.1 SHIPPING, RECEIPT AND STORAGE OF STRAINS ..................................................................................................... 2 
4 DETECTION AND IDENTIFICATION OF MRSA FROM SWAB SAMPLES ............................................... 2 
4.1 SELECTIVE ENRICHMENT AND ISOLATION ............................................................................................................ 2 
4.2 IDENTIFICATION OF MRSA .................................................................................................................................. 3 
4.3 SPA TYPING .......................................................................................................................................................... 3 
5 REPORTING OF RESULTS AND EVALUATION ............................................................................................. 3 
6 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE ................................................................ 4 
 
 
1 Introduction 
One of the tasks as the European Union Reference Laboratory for Antimicrobial Resistance (EURL-
AR) is to organise and conduct External Quality Assurance Systems (EQAS’s). Usually the EQAS’s 
have been focused on susceptibility testing, however, due to the recent concern about FA-MRSA 
(farm acquired methicillin resistant Staphylococcus aureus) detected in European farms and the 
recently performed baseline screening performed aiming at the detection of FA-MRSA in pig farms, 
we have now decided to continue the MRSA EQAS to evaluate the proficiency of the laboratories 
on the selective isolation procedures for detection of MRSA, including their confirmatory testing 
and spa typing.  
As referred in the pre-notification, this EQAS is designed specifically for designated NRL-ARs and 
additional designated laboratories performing the selective isolation and identification of MRSA 
from pig farms. 
In this MRSA EQAS we have prepared swab samples, which should be processed according to the 
description found in this protocol. 
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2 Objectives 
The main objective of this EQAS is to support laboratories in assessing and if necessary improve 
the quality of selective isolation for detection, confirmatory testing and spa-typing of MRSA. 
Furthermore, to assess and improve the comparability of the baseline screening data reported to 
EFSA by different laboratories within the EU. 
 
3 Outline of the MRSA EQAS 2012 
 
3.1 Shipping, receipt and storage of strains 
In October 2012 all EU appointed National Reference Laboratories (or the alternative laboratories 
that have processed the MRSA baseline sample analysis) will receive a parcel from the EURL-AR 
containing eight swab samples which contain a background flora and might contain MRSA (some 
samples will be negative, or contain other methicillin susceptible or resistant Staphylococcus 
strains). 
NOTE:
 
 The samples should be received and processed immediately upon arrival, or as quickly as 
possible to assure the stability of the samples. Please take note of the day you start the isolation 
procedure and provide this information in our database.  
4 Detection and identification of MRSA from swab samples 
 
4.1 Selective enrichment and isolation 
1. In the laboratory, open carefully the tubes containing the swab samples in transport medium 
(in a laminar air flow bench and using protective gloves) and inoculate each swab into a tube 
containing 10 ml of Mueller-Hinton broth supplemented with 6.5 % NaCl. Mix thoroughly.  
2. Incubate at 37 °C for 16-20 h. 
3. Take one millilitre of this first pre-enrichment culture and then inoculate into 9 ml Tryptone 
Soya Broth with 3.5 mg/L cefoxitin and 75 mg/L aztreonam. Mix thoroughly.  
4. Incubate for 16-20 h at 37 °C. 
5. Take one loop-full (10µl loop) of the latter selective enriched culture and streak onto a 
Brilliance MRSA Chromogenic Agar plate (Oxoid) and a blood agar plate.  
6. Incubate 24-48 h at 37 °C.  
 
EU Reference Laboratory for Antimicrobial Resistance  
MRSA External Quality Assurance System (EQAS) 2012                                                  Page 3 of 5 
 
5.09.2012 
7. Observe the colony morphology (size and coloration) of the colonies obtained on the 
Brilliance MRSA Chromogenic Agar plate, choose up to five blue colonies indicative for 
being MRSA and isolate them from the MRSA selective plate onto a new blood agar plate. 
The additional blood agar plate obtained from inoculation of the selective broth is used for 
parallel observation with the MRSA plate to double-check the colony morphology (to 
observe typical S. aureus morphology and haemolysis), but should not be used for isolation. 
8. Incubate the new blood agar plates containing the isolates during 24h at 37ºC. 
9. Observe the colony morphology of the isolates on the blood agar plate (colour, appearance, 
haemolysis). Check for purity and re-isolate if necessary.  
10. Presumptive isolates of methicillin resistant Staphylococcus aureus should at this stage 
either be stored under appropriate conditions (–80°C) for later identification and 
characterisation or processed immediately. 
 
4.2 Identification of MRSA 
Presumptive MRSA isolates should be confirmed as Staphylococcus aureus isolates carrying the 
mecA gene or the mecC gene (previously known by mecALGA251) by PCR. There is no need to 
perform other screening methods (such as screening with either oxacillin or cefoxitin) if the isolates 
have been obtained from selective isolation, thus, the presence of the mecA or mecC gene can be 
directly confirmed by PCR amplification. The species identification is simultaneously confirmed by 
using the new EURL-AR recommended multiplex PCR protocol including the amplification of the 
spa gene (specific for Staphylococcus aureus species and which may be sequenced for spa typing), 
the  mecA-gene and the mecC gene (encoding methicillin resistance) and the pvl gene (encoding the 
Panton Valentine Leukocidin), which should be performed according to the new EURL-AR 
recommended protocol (http://www.eurl-ar.eu/233-protocols.htm 
 
).  
4.3 Spa typing  
Spa typing of the MRSA isolates may be performed additionally if the laboratory has the capacity to 
perform and analyse the spa- typing data. In case you decide to include spa types in the data 
submitted, these will be evaluated on the accuracy of the spa typing. 
 
5 Repor ting of results and evaluation 
Fill in your results in the enclosed test form. Please enter your results into the interactive web 
database. Please read the detailed description below before entering the web database. When you 
enter the results via the web, you will be guided through all steps on the screen and you will 
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immediately be able to view and print a submission report of your results. Please submit results by 
latest December 14th 2012. After the deadline, the database will be closed and you will be able to 
view and print an automatically generated report evaluating your results
If you experience difficulties entering the data, please return results by e-mail, fax or mail to the 
EURL-AR.  
. 
All results will be summarized in a report which will be made available to all participants. The data 
in the report will be presented with laboratory codes. A laboratory code is known to the individual 
laboratory, whereas the entire list of laboratories and their codes is confidential and known only to 
the EURL-AR and the EU Commission. All conclusions are public. 
If you have any questions, please do not hesitate to contact the MRSA EQAS Coordinator: 
 
Lina Cavaco  
The National Food Institute 
Technical University of Denmark 
Kemitorvet Building 204 Ground floor,  
DK-2800 Kongens Lyngby 
Denmark 
Tel: +45 3588 6269  
Fax: +45 3588 6341  
E-mail: licav@food.dtu.dk 
6 How to enter  results in the interactive database 
Please read this passage before entering the web page. Before you go ahead, you need your test 
form.  
You are able to browse back and forth by using the forward and back keys or click on the EURL 
logo. 
You enter the EURL-AR EQAS 2012 start web page (http://thor.dfvf.dk/eurl) then write your 
username and password in low cases and press enter. Your username and password is the same as in 
the previous EQAS’s arranged by The National Food Institute. If you have problems with the login 
please contact us.  
Click on “MRSA tests” to start entering your data regarding the MRSA EQAS. 
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Please read carefullly the instructions on the webpage and start by answering to the questionnaire on 
the work performed in your laboratory relative to MRSA by clicking on “General MRSA 
questionnaire”.  
Please choose the options that more correctly describe your work on MRSA and before you leave 
this page click on “Save page” which will take you back to the previous menu. 
 
Then, we will ask you to fill in the methods used in a second page which you will reach by clicking 
on “ Methods for MRSA test samples.” 
In the next page you navigate to fields with the Tab-key and mouse.  
Fill in what kind of method you have used for the selective isolation and confirmation of MRSA in 
this EQAS.  
Click on "Save and go to the next page”  
In the data entry pages for each sample “EURL-MRSA 4.1, …”, you enter the obtained results for 
each of the MRSA EQAS samples. 
If you wish so, you will have the option to include the spa-typing results. 
If you did not perform spa typing leave the field blank , in case you have obtained an isolate but it is 
not a methicillin resistant Staphylococcus aureus, choose “not applicable (N/A)”, otherwise if you 
have performed the spa typing, choose the spa type from the list. Click on "save and go to next 
page" to navigate to the next sample results, until you finish to upload all your data. 
From the last result sheet you get into the general menu, from where you can review the input pages, 
approve your input and finally see and print the evaluated results: 
Browse through the pages and make corrections if necessary. Remember to save a page if you make 
any corrections. If you save a page without changes, you will see an error screen, and you just have 
to click on "back" to get back to the page and "go to next page" to continue. 
At the end, approve your input. Be sure that you have filled in all the results before approval, as 
YOU CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive 
database, but allows you to see the submitted results.  
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Appendix 5- Example of Test forms MRSA EQAS 2012 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
How many samples did you process in 2011 for MRSA detection? (Choose only one option) 
 less than 50 
 50-100 
 101- 200 
 201-400 
 more than 400 
 
Which kind of samples did you process in your laboratory for MRSA detection in 2011?  
 dust swabs 
  nasal swabs 
  skin swabs 
  faecal samples 
  other matrices  Specify:       
 
Which was the origin of the samples processed for MRSA detection in 2011?  
  from humans 
  environmental 
 from animals  if  you check this answer, please answer the next question 
 other .  Specify:       
 
The samples processed from animals included samples obtained from which species: 
  pigs 
  cattle 
 poultry 
 pets 
 other .  Specify:       
 
 
Any other Comments:       
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TEST FORM – MRSA methods                                                           
Method used for selective isolation of MRSA in this EQAS:  
 
 Selective isolation procedure using the exact protocol  
 
  different enrichment, agar plates or incubation conditions 
 If you used different pre enrichment please indicate: 
 Salt concentration used in the Müller Hinton broth:      % 
 Other medium:      
 If you used different enrichment please indicate 
 Cefoxitin concentration:     mg/L 
 Aztreonam concentration:       mg/L 
 Other modifications: medium antimicrobials or concentrations: 
       
 
 If you used different selective agar plates 
 Different agar brand:                            
 
 If you used different incubation conditions 
Specify:  pre enrichment      °C/     h;  
                      selective enrichment      °C/     h;  
 selective plating      °C/     h  
 
Method used for confirmatory testing of MRSA (choose only one option) 
 
 PCR using the new EURL recommended multiplex PCR protocol (spa, mecA, 
mecC,and pvl) 
 PCR using the old EURL multiplex PCR protocol (16S rDNA, mecA and nuc) 
  modified protocol but same multiplex PCR primers 
  other published PCR method 
  in- house PCR method 
Describe if you did not use the new EURL recommended method and justify your 
choice:                            
  
Method used for confirmation of species identification (choose only one option) 
 
 PCR using the new EURL recommended multiplex PCR protocol (spa, mecA, 
mecC,and pvl) 
 PCR using the old EURL multiplex PCR protocol (16S rDNA, mecA and nuc) 
  biochemical methods 
  other published PCR method 
  in-house PCR method 
 
Describe if you did not use the EURL recommended method and justify your choice:                
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TEST FORM                                                            
Entry data Sample EURL-MRSA 4.X 
 
Date the isolation procedure was started:       
 
Please describe the results you have observed regarding this swab sample: 
Growth in pre-enrichment:  
 Yes  /  No  
 
Growth in selective enrichment: 
 Yes /  No  
 
Growth in MRSA selective plates: 
 Yes  /  No  
 
Please describe the growth observed on MRSA selective plates?  (choose only one option) 
 Mixed culture containing typical colonies 
 Mixed culture without typical colonies 
 Pure culture of typical colonies 
 Pure culture without typical colonies 
 No growth 
 
Results of confirmatory PCR and species identification: (choose only one option) 
 no isolates tested, sample negative 
 mecA positive, but coagulase-negative Staphylococci (MRCNS) 
 mecA positive, but S . pseudintermedius (MRSP) 
 mecA and mecC negative and not S . aureus (CNS) 
 mecA and mecC negative, S. aureus (MSSA) 
 mecA positive, S. aureus (MRSA)  
 mecC positive, S. aureus (MRSA)  
 
Spa Typing (optional): spa type (choose only one option) 
 Not performed 
 Not applicable (N/A) 
 t011 
 t021 
 t034 
 t075 
 t108 
 t127 
 t337 
 t524 
 t571 
 t843 
 t899 
 t1333 
 t1430 
 t1730 
 t1793 
 t2510 
 t2922 
National Food Institute
Technical University of Denmark
Kemitorvet, 204
DK - 2800 Kgs. Lyngby
Tel.   35 88  70 00
Fax   35 88  70 01
www.food.dtu.dk 
ISBN:  978-87-92763-81-5
